Create Medic Co., Ltd. Revises FY2026 Earnings Down 25%
Create Medic Co., Ltd. (TSE:5187) has downwardly revised its full-year earnings forecast for the fiscal year ending December 2026, citing margin pressure from intensified Chinese procurement competition and yen weakness.
| Item | Before | After | Change |
|---|---|---|---|
| Revenue | JPY 14.0bn | JPY 14.0bn | +0.0% |
| Operating Profit | JPY 1.06bn | JPY 760M | -28.3% |
| Ordinary Income | JPY 1.07bn | JPY 800M | -25.2% |
| Net Profit | — | — | — |
| EPS | JPY 89.44/share | JPY 68.90/share | JPY -20.54/share |
The medical device manufacturer maintained its revenue guidance at JPY 14.0bn but slashed operating profit by JPY 300M (-28.3%), ordinary income (keijo rieki) by JPY 270M (-25.2%), and net profit by JPY 190M (-25.3%). The revision reflects two primary headwinds: deteriorating profitability margins from competitive bidding pressures in China’s centralized procurement system, and unfavorable currency movements as the yen weakened against major trading partners. The company cited second-quarter consolidated results and revised business environment assessments as the basis for the adjustment.
The across-the-board profit contraction signals structural margin compression despite stable top-line performance. International investors should note that ordinary income—a Japan-specific metric encompassing operating profit plus non-operating items like interest and dividend income—declined 25.2%, indicating the margin pressure extends beyond core operations. The sharp downward revision raises concerns about sustained profitability headwinds in the company’s key markets, particularly as Chinese healthcare procurement consolidation continues to intensify competitive dynamics.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.